Author

T. W. Schacker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:clinical cohort / trial· 1 Approach:experimental assay· 1 Assay:metagenomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Chokola· 1 shared A. Horowitz· 1 shared A. K. Rosenstein· 1 shared A. La Porte· 1 shared A. Seki· 1 shared A. Velez· 1 shared B. K. Chen· 1 shared C. A. Broedlow· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Chokola

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized COVID-19 patients

C. M. Basting, R. Langat, C. A. Broedlow, C. Guerrero, T. D. Bold, M. Bailey, A. Velez, T. Schroeder, J. Short-Miller, R. Cromarty, Z. Mayer, P. J. Southern, T. W. Schacker, S. E. Safo, C. T. Bramante, , N. R. Klatt

This study examines the impact of SARS-CoV-2 infection on intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients, finding associations between specific microbial changes and disease severity.

bioRxiv · Dec 7, 2023 · PreprintMicrobiology

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals

M. Uzzan, M. Tokuyama, A. K. Rosenstein, C. Tomescu, I. N. SahBandar, H. M. Ko, L. Leyre, A. Chokola, E. Kaplan-Lewis, G. Rodriguez, A. Seki, M. J. Corley, J. Aberg, A. La Porte, E.-y. Park, , S. Mehandru

Anti-α4β7 therapy reduces lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals with mild inflammatory bowel disease.

bioRxiv · Jun 14, 2018Immunology